{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:55:51Z","timestamp":1770771351872,"version":"3.50.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Bioinformatics"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Gene expression connectivity mapping has gained much popularity recently with a number of successful applications in biomedical research testifying its utility and promise. Previously methodological research in connectivity mapping mainly focused on two of the key components in the framework, namely, the reference gene expression profiles and the connectivity mapping algorithms. The other key component in this framework, the query gene signature, has been left to users to construct without much consensus on how this should be done, albeit it has been an issue most relevant to end users. As a key input to the connectivity mapping process, gene signature is crucially important in returning biologically meaningful and relevant results. This paper intends to formulate a standardized procedure for constructing high quality gene signatures from a user\u2019s perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We describe a two-stage process for making quality gene signatures using gene expression data as initial inputs. First, a differential gene expression analysis comparing two distinct biological states; only the genes that have passed stringent statistical criteria are considered in the second stage of the process, which involves ranking genes based on statistical as well as biological significance. We introduce a \u201cgene signature progression\u201d method as a standard procedure in connectivity mapping. Starting from the highest ranked gene, we progressively determine the minimum length of the gene signature that allows connections to the reference profiles (drugs) being established with a preset target false discovery rate. We use a lung cancer dataset and a breast cancer dataset as two case studies to demonstrate how this standardized procedure works, and we show that highly relevant and interesting biological connections are returned. Of particular note is gefitinib, identified as among the candidate therapeutics in our lung cancer case study. Our gene signature was based on gene expression data from Taiwan female non-smoker lung cancer patients, while there is evidence from independent studies that gefitinib is highly effective in treating women, non-smoker or former light smoker, advanced non-small cell lung cancer patients of Asian origin.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In summary, we introduced a gene signature progression method into connectivity mapping, which enables a standardized procedure for constructing high quality gene signatures. This progression method is particularly useful when the number of differentially expressed genes identified is large, and when there is a need to prioritize them to be included in the query signature. The results from two case studies demonstrate that the approach we have developed is capable of obtaining pertinent candidate drugs with high precision.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12859-016-1066-x","type":"journal-article","created":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T12:01:29Z","timestamp":1462968089000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["A gene-signature progression approach to identifying candidate small-molecule cancer therapeutics with connectivity mapping"],"prefix":"10.1186","volume":"17","author":[{"given":"Qing","family":"Wen","sequence":"first","affiliation":[]},{"given":"Chang-Sik","family":"Kim","sequence":"additional","affiliation":[]},{"given":"Peter W.","family":"Hamilton","sequence":"additional","affiliation":[]},{"given":"Shu-Dong","family":"Zhang","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,5,11]]},"reference":[{"issue":"16","key":"1066_CR1","doi-asserted-by":"publisher","first-page":"3738","DOI":"10.1002\/cncr.24417","volume":"115","author":"C Braconi","year":"2009","unstructured":"Braconi C, Meng FY, Swenson E, Khrapenko L, Huang NY, Patel T. Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. Cancer. 2009; 115(16):3738\u2013748. doi:10.1002\/cncr.24417.","journal-title":"Cancer"},{"issue":"11","key":"1066_CR2","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1097\/JTO.0b013e31822adfb0","volume":"6","author":"AK Reka","year":"2011","unstructured":"Reka AK, Kuick R, Kurapati H, Standiford TJ, Omenn GS, Keshamouni VG. Identifying inhibitors of epithelial-mesenchymal transition by connectivity map-based systems approach. J Thorac Oncol. 2011; 6(11):1784\u20131792. doi:10.1097\/JTO.0b013e31822adfb0.","journal-title":"J Thorac Oncol"},{"issue":"12","key":"1066_CR3","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/cdd.2012.108","volume":"19","author":"S Varadarajan","year":"2012","unstructured":"Varadarajan S, Bampton ETW, Smalley JL, Tanaka K, Caves RE, Butterworth M, Wei J, Pellecchia M, Mitcheson J, Gant TW, Dinsdale D, Cohen GM. A novel cellular stress response characterised by a rapid reorganisation of membranes of the endoplasmic reticulum. Cell Death Differ. 2012; 19(12):1896\u20131907. doi:10.1038\/cdd.2012.108.","journal-title":"Cell Death Differ"},{"issue":"23-24","key":"1066_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.drudis.2012.07.017","volume":"17","author":"XYA Qu","year":"2012","unstructured":"Qu XYA, Rajpal DK. Applications of connectivity map in drug discovery and development. Drug Discov Today. 2012; 17(23-24):1289\u201398.","journal-title":"Drug Discov Today"},{"issue":"7-8","key":"1066_CR5","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.drudis.2012.07.014","volume":"18","author":"F Iorio","year":"2013","unstructured":"Iorio F, Rittman T, Ge H, Menden M, Saez-Rodriguez J. Transcriptional data: a new gateway to drug repositioning?. Drug Discov Today. 2013; 18(7-8):350\u20137. doi:10.1016\/j.drudis.2012.07.014.","journal-title":"Drug Discov Today"},{"issue":"7","key":"1066_CR6","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1002\/stem.1398","volume":"31","author":"JM Ramsey","year":"2013","unstructured":"Ramsey JM, Kettyle LMJ, Sharpe DJ, Mulgrew NM, Dickson GJ, Bijl JJ, Austin P, Mayotte N, Cellot S, Lappin TRJ, Zhang SD, Mills KI, Krosl J, Sauvageau G, Thompson A. Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia. Stem Cells. 2013; 31(7):1434\u201345. doi:10.1002\/stem.1398.","journal-title":"Stem Cells"},{"issue":"7","key":"1066_CR7","first-page":"2202","volume":"5","author":"W Zhuo","year":"2015","unstructured":"Zhuo W, Zhang L, Zhu Y, Xie Q, Zhu B, Chen Z. Valproic acid, an inhibitor of class i histone deacetylases, reverses acquired erlotinib-resistance of lung adenocarcinoma cells: a connectivity mapping analysis and an experimental study. Am J Cancer Res. 2015; 5(7):2202\u201311.","journal-title":"Am J Cancer Res"},{"key":"1066_CR8","doi-asserted-by":"crossref","unstructured":"Siavelis JC, Bourdakou MM, Athanasiadis EI, Spyrou GM, Nikita KS. Bioinformatics methods in drug repurposing for alzheimer\u2019s disease. Brief Bioinform. 2015. doi:10.1093\/bib\/bbv048.","DOI":"10.1093\/bib\/bbv048"},{"issue":"3","key":"1066_CR9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.tox.2009.09.014","volume":"268","author":"JL Smalley","year":"2010","unstructured":"Smalley JL, Gant TW, Zhang SD. Application of connectivity mapping in predictive toxicology based on gene-expression similarity. Toxicology. 2010; 268(3):143\u20136. doi:10.1016\/j.tox.2009.09.014.","journal-title":"Toxicology"},{"issue":"1","key":"1066_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/carcin\/bgt278","volume":"35","author":"F Caiment","year":"2014","unstructured":"Caiment F, Tsamou M, Jennen D, Kleinjans J. Assessing compound carcinogenicity in vitro using connectivity mapping. Carcinogenesis. 2014; 35(1):201\u20137. doi:10.1093\/carcin\/bgt278.","journal-title":"Carcinogenesis"},{"issue":"5795","key":"1066_CR11","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR. The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease. Science. 2006; 313(5795):1929\u201335. doi:10.1126\/science.1132939.","journal-title":"Science"},{"issue":"8","key":"1066_CR12","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.4161\/auto.6.8.13551","volume":"6","author":"F Iorio","year":"2010","unstructured":"Iorio F, Isacchi A, di Bernardo D, Brunetti-Pierri N. Identification of small molecules enhancing autophagic function from drug network analysis. Autophagy. 2010; 6(8):1204\u20135.","journal-title":"Autophagy"},{"issue":"96","key":"1066_CR13","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/scitranslmed.3001318","volume":"3","author":"M Sirota","year":"2011","unstructured":"Sirota M, Dudley JT, Kim J, Chiang AP, Morgan AA, Sweet-Cordero A, Sage J, Butte AJ. Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med. 2011; 3(96):96\u201377.","journal-title":"Sci Transl Med"},{"issue":"96","key":"1066_CR14","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1126\/scitranslmed.3002648","volume":"3","author":"JT Dudley","year":"2011","unstructured":"Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, Chiang AP, Morgan AA, Sarwal MM, Pasricha PJ, Butte AJ. Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med. 2011; 3(96):96\u201376.","journal-title":"Sci Transl Med"},{"issue":"6","key":"1066_CR15","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.cmet.2011.03.020","volume":"13","author":"SD Kunkel","year":"2011","unstructured":"Kunkel SD, Suneja M, Ebert SM, Bongers KS, Fox DK, Malmberg SE, Alipour F, Shields RK, Adams CM. mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle mass. Cell Metab. 2011; 13(6):627\u201338.","journal-title":"Cell Metab"},{"issue":"1","key":"1066_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/bib\/bbn041","volume":"9","author":"SD Zhang","year":"2008","unstructured":"Zhang SD, Gant TW. A simple and robust method for connecting small-molecule drugs using gene-expression signatures. BMC Bioinforma. 2008; 9(1):1\u201310. doi:10.1186\/1471-2105-9-258.","journal-title":"BMC Bioinforma"},{"key":"1066_CR17","doi-asserted-by":"crossref","unstructured":"Zhang SD, Gant TW. sscmap: An extensible java application for connecting small-molecule drugs using gene-expression signatures. Bmc Bioinforma. 2009;10. doi:10.1186\/1471-2105-10-236.","DOI":"10.1186\/1471-2105-10-236"},{"key":"1066_CR18","doi-asserted-by":"crossref","unstructured":"Segal MR, Xiong H, Bengtsson H, Bourgon R, Gentleman R. Querying genomic databases: Refining the connectivity map. Stat Appl Genet Mol Biol. 2012;11(2). doi:10.2202\/1544-6115.1715.","DOI":"10.2202\/1544-6115.1715"},{"issue":"9","key":"1066_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pcbi.1000925","volume":"6","author":"M Iskar","year":"2010","unstructured":"Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, Bork P. Drug-induced regulation of target expression. PLoS Comput Biol. 2010; 6(9):1\u20138. doi:10.1371\/journal.pcbi.1000925.","journal-title":"PLoS Comput Biol."},{"issue":"33","key":"1066_CR20","doi-asserted-by":"publisher","first-page":"14621","DOI":"10.1073\/pnas.1000138107","volume":"107","author":"F Iorio","year":"2010","unstructured":"Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, di Bernardo D. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci USA. 2010; 107(33):14621\u201326.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1066_CR21","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/1471-2105-12-369","volume":"12","author":"MN McCall","year":"2011","unstructured":"McCall MN, Irizarry RA. Thawing Frozen Robust Multi-array Analysis (fRMA). BMC Bioinforma. 2011; 12:369.","journal-title":"BMC Bioinforma"},{"key":"1066_CR22","doi-asserted-by":"crossref","unstructured":"Kim CS, Hwang S, Zhang SD. Rma with quantile normalization mixes biological signals between different sample groups in microarray data analysis. In: Bioinformatics and Biomedicine (BIBM), 2014 IEEE International Conference On: 2014. p. 139\u201343, doi:10.1109\/BIBM.2014.6999142.","DOI":"10.1109\/BIBM.2014.6999142"},{"issue":"4","key":"1066_CR23","doi-asserted-by":"publisher","first-page":"18874","DOI":"10.1371\/journal.pone.0018874","volume":"6","author":"SD Zhang","year":"2011","unstructured":"Zhang SD. Towards accurate estimation of the proportion of true null hypotheses in multiple testing. PLoS ONE. 2011; 6(4):18874.","journal-title":"PLoS ONE"},{"issue":"4","key":"1066_CR24","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/j.0006-341X.2003.00123.x","volume":"59","author":"CA Tsai","year":"2003","unstructured":"Tsai CA, Hsueh HM, Chen JJ. Estimation of false discovery rates in multiple testing: application to gene microarray data. Biometrics. 2003; 59(4):1071\u201381.","journal-title":"Biometrics"},{"issue":"10","key":"1066_CR25","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1158\/1055-9965.EPI-10-0332","volume":"19","author":"TP Lu","year":"2010","unstructured":"Lu TP, Tsai MH, Lee JM, Hsu CP, Chen PC, Lin CW, Shih JY, Yang PC, Hsiao CK, Lai LC, Chuang EY. Identification of a novel biomarker, SEMA5A, for non-small cell lung carcinoma in nonsmoking women. Cancer Epidemiol Biomarkers Prev. 2010; 19(10):2590\u201397.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"1066_CR26","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1093\/bioinformatics\/btg405","volume":"20","author":"L Gautier","year":"2004","unstructured":"Gautier L, Cope L, Bolstad BM, Irizarry RA. affy\u2013analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004; 20(3):307\u201315.","journal-title":"Bioinformatics"},{"issue":"1","key":"1066_CR27","doi-asserted-by":"publisher","first-page":"16382","DOI":"10.1371\/journal.pone.0016382","volume":"6","author":"DG McArt","year":"2011","unstructured":"McArt DG, Zhang SD. Identification of candidate small-molecule therapeutics to cancer by gene-signature perturbation in connectivity mapping. PLoS ONE. 2011; 6(1):16382.","journal-title":"PLoS ONE"},{"issue":"4","key":"1066_CR28","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.prp.2009.11.006","volume":"206","author":"IB Pau Ni","year":"2010","unstructured":"Pau Ni IB, Zakaria Z, Muhammad R, Abdullah N, Ibrahim N, Aina Emran N, Hisham Abdullah N, Syed Hussain SN. Gene expression patterns distinguish breast carcinomas from normal breast tissues: the Malaysian context. Pathol Res Pract. 2010; 206(4):223\u20138.","journal-title":"Pathol Res Pract"},{"issue":"4","key":"1066_CR29","first-page":"971","volume":"7","author":"DM Vigushin","year":"2001","unstructured":"Vigushin DM, Ali S, Pace PE, Mirsaidi N, Ito K, Adcock I, Coombes RC. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res. 2001; 7(4):971\u20136.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1066_CR30","doi-asserted-by":"publisher","first-page":"91610","DOI":"10.1371\/journal.pone.0091610","volume":"9","author":"S Sun","year":"2014","unstructured":"Sun S, Han Y, Liu J, Fang Y, Tian Y, Zhou J, Ma D, Wu P. Trichostatin A targets the mitochondrial respiratory chain, increasing mitochondrial reactive oxygen species production to trigger apoptosis in human breast cancer cells. PLoS ONE. 2014; 9(3):91610.","journal-title":"PLoS ONE"},{"issue":"1","key":"1066_CR31","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s13277-012-0544-7","volume":"34","author":"M Tavakoli-Yaraki","year":"2013","unstructured":"Tavakoli-Yaraki M, Karami-Tehrani F, Salimi V, Sirati-Sabet M. Induction of apoptosis by Trichostatin A in human breast cancer cell lines: involvement of 15-Lox-1. Tumour Biol. 2013; 34(1):241\u20139.","journal-title":"Tumour Biol"},{"issue":"2","key":"1066_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1023\/A:1016121822916","volume":"74","author":"RW Brueggemeier","year":"2002","unstructured":"Brueggemeier RW. Overview of the pharmacology of the aromatase inactivator exemestane. Breast Cancer Res Treat. 2002; 74(2):177\u201385.","journal-title":"Breast Cancer Res Treat"},{"key":"1066_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1476-4598-8-109","volume":"8","author":"A Koutras","year":"2009","unstructured":"Koutras A, Giannopoulou E, Kritikou I, Antonacopoulou A, Evans TR, Papavassiliou AG, Kalofonos H. Antiproliferative effect of exemestane in lung cancer cells. Mol Cancer. 2009; 8:109.","journal-title":"Mol Cancer"},{"key":"1066_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1476-4598-13-69","volume":"13","author":"B Nuvoli","year":"2014","unstructured":"Nuvoli B, Germoni S, Morosetti C, Santoro R, Cortese G, Masi S, Cordone I, Galati R. Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease. Mol Cancer. 2014; 13:69.","journal-title":"Mol Cancer"},{"issue":"1","key":"1066_CR35","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/01.sla.0000149427.84712.d9","volume":"241","author":"T Tanaka","year":"2005","unstructured":"Tanaka T, Delong PA, Amin K, Henry A, Kruklitis R, Kapoor V, Kaiser LR, Albelda SM. Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery. Ann Surg. 2005; 241(1):168\u201378.","journal-title":"Ann Surg"},{"issue":"10","key":"1066_CR36","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMoa0810699","volume":"361","author":"TS Mok","year":"2009","unstructured":"Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947\u201357.","journal-title":"N Engl J Med"}],"container-title":["BMC Bioinformatics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-016-1066-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12859-016-1066-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-016-1066-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12859-016-1066-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T18:03:56Z","timestamp":1706810636000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbioinformatics.biomedcentral.com\/articles\/10.1186\/s12859-016-1066-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,11]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12]]}},"alternative-id":["1066"],"URL":"https:\/\/doi.org\/10.1186\/s12859-016-1066-x","relation":{},"ISSN":["1471-2105"],"issn-type":[{"value":"1471-2105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,11]]},"assertion":[{"value":"29 December 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"211"}}